Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome

被引:101
作者
Choquet-Kastylevsky, G
Intrator, L
Chenal, C
Bocquet, H
Revuz, J
Roujeau, JC
机构
[1] Univ Paris 12, Hop Henri Mondor, Dept Dermatol, F-94010 Creteil, France
[2] Univ Paris 12, Hop Henri Mondor, Dept Immunol, F-94010 Creteil, France
关键词
D O I
10.1046/j.1365-2133.1998.02559.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Hypersensitivity syndrome (HSS) usually refers to severe drug eruption associated with systemic symptoms and eosinophilia. Interleukin (a)-5 regulates eosinophil counts with the help of IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Blood IL-5 levels have been reported to be increased in patients with eosinophila secondary to parasitic infections or idiopathic eosinophilia. but have never been evaluated in drug-induced eosinophilia. The aim of our study was to determine whether IL-5, IL-3 and GM-CSF are involved in eosinophilia in patients with drug-induced HSS. Plasma levels of IL-3, IL-5 and GM-CSF were assayed by ELISA in seven patients with drug-induced HSS, in eight patients with cutaneous adverse drug reactions not associated with eosinophilia, and in five patients with eosinophilia unrelated to drug treatment. IL-5 levels were normal in all eight patients with drug eruptions without eosinophilia, and increased in five of the seven patients with HSS. In the latter patients, IL-5 levels peaked several days before highest eosinophil counts were noted, and returned to normal within a few days, even when eosinophilia persisted. In patients with eosinophilia unrelated to drug treatment, IL-5 levels, although significantly increased, remained lower than in HSS patients. IL-3 and GR I-CSF could not be detected in any group, at any time. Our results show that IL-5 is involved in drug-related eosinophilia. As IL-5 production was only Involved in the early stages of the reaction, it is suggested that IL-5 mainly derives from activated lymphocytes rather than eosinophils. Our results support the clinical relevance of previous in vitro findings. Further studies are needed to test whether assays of IL-5 production by lymphocytes of patients stimulated by the suspected drug and/or its metabolites, are useful in establishing causality in drug-induced reactions associated with eosinophilia.
引用
收藏
页码:1026 / 1032
页数:7
相关论文
共 39 条
[31]  
TSUTSUI H, 1992, J IMMUNOL, V149, P706
[32]   PATCH TESTING WITH CARBAMAZEPINE - REINDUCTION OF AN EXFOLIATIVE DERMATITIS [J].
VAILLANT, L ;
CAMENEN, I ;
LORETTE, G .
ARCHIVES OF DERMATOLOGY, 1989, 125 (02) :299-299
[33]   Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung [J].
Venge, J ;
Lampinen, M ;
Hakansson, L ;
Rak, S ;
Venge, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (05) :1110-1115
[34]   ANTICONVULSANT HYPERSENSITIVITY SYNDROME [J].
VITTORIO, CC ;
MUGLIA, JJ .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (21) :2285-2290
[35]  
WELLER PF, 1991, NEW ENGL J MED, V324, P1110
[36]   Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis [J].
Wolkenstein, P ;
Chosidow, O ;
Flechet, ML ;
Robbiola, O ;
Paul, M ;
Dume, L ;
Revuz, J ;
Roujeau, JC .
CONTACT DERMATITIS, 1996, 35 (04) :234-236
[37]   METABOLIC PREDISPOSITION TO CUTANEOUS ADVERSE DRUG-REACTIONS - ROLE IN TOXIC EPIDERMAL NECROLYSIS CAUSED BY SULFONAMIDES AND ANTICONVULSANTS [J].
WOLKENSTEIN, P ;
CHARUE, D ;
LAURENT, P ;
REVUZ, J ;
ROUJEAU, JC ;
BAGOT, M .
ARCHIVES OF DERMATOLOGY, 1995, 131 (05) :544-551
[38]  
YAMAGUCHI Y, 1990, EXP HEMATOL, V18, P1152
[39]  
Zanni MP, 1997, J IMMUNOL, V158, P1139